Brief: Ionis Partner Biogen Announces Topline Results From Phase 2 Celia Study Of Diranersen
14/05/2026 12:05
May 14 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS PARTNER BIOGEN ANNOUNCES TOPLINE RESULTS FROM PHASE 2 CELIA STUDY OF DIRANERSEN (BIIB080): FIRST STUDY TO SHOW REDUCTION IN TAU PATHOLOGY AND COGNITIVE BENEFIT IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Source text: ID:nBw5Mb3ya Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study